吉利德发布了乙型肝炎治疗的研究结果

StephenW

Gilead’s releases research results for hepatitis B treatment

    By Lee Han-soo
    Published 2018.11.28 15:34
    Updated 2018.11.28 15:34
    comments 0

    Gilead Science Korea said it has presented the data on the significance of the early achievement of normalizing alanine aminotransferase (ALT) levels in chronic hepatitis B treatment, at the Asian Pacific Digestive Week 2018.

Chaired by Professor Henry Chan from the Chinese University of Hong Kong, Professors Pietro Lampertico of the Università degli Studi di Milan and Lim Young-seok of University of Ulsan College of Medicine presented their findings.

According to Professor Chan, patients with chronic hepatitis B aged 50 years or older increased about twice as much between 2011 and 2015 compared to the 2000-2005period. Also, the percentage of chronic hepatitis B patients with chronic kidney disease, osteoporosis, and osteopenia increased by 16, 6, and 8 percent, respectively, in 2011-2015 compared to 2000-2005.

Professor Lampertico explained the changing dynamics of patient aging.

“The newly launched chronic hepatitis B treatment Vemlidy is attracting attention with its improved plasma stability, efficient drug delivery, and improved kidney and bone safety profiles,” he said. “Vemlidy has demonstrated inferior antiviral efficacy, improved renal and bone safety, and high resistance barriers compared to Viread at the end of 96 weeks of a large phase 3 clinical trial.”

Recent studies have also proved that Vemlidy also has higher ALT normalization reach rates than Viread, he added.

With such results, Professor Lampertico presented the latest findings that early normalization of ALT levels can lower the incidence of liver cancer.

The company conducted a cohort study in Hong Kong by treating 21,182 chronic hepatitis B patients treated with tenofovir disoproxil fumarate (TDF) and Entecavir (ETV) from 2005 to 2016, with a follow-up period of 12 months.

As a result, the incidence of hepatocellular carcinoma in patients that achieved ALT normalization values (male <30 U/L, female <19 U/L) was 2.7 percent, which was significantly lower than patients who did not achieve ALT normalization within the same period.

Patients with ALT levels above 2x upper limit of normal (ULN) at 12 months had an incidence of liver cancer of approximately 6 percent, while patients between 1 and 2x ULN had a frequency of roughly 4.6 percent, according to the Italian expert.

Professor Lim Young-seok also presented that TDF group among oral antiviral drugs had a lower incidence of liver cancer than ETV group.

“Both national cohort and hospital cohort studies showed that the TDF-treated group had a lower incidence of liver cancer than the ETV-treated group,” Professor Lim said.

[email protected]

StephenW

吉利德发布了乙型肝炎治疗的研究结果

    李汉洙
    发布时间2018.11.28 15:34
    更新时间：2018.11.28 15:34
    评论0

    Gilead Science Korea表示，它已经提供了关于早期实现慢性乙型肝炎治疗中丙氨酸氨基转移酶（ALT）水平正常化的重要性的数据，在2018年亚太消化周。

由香港中文大学的Henry Chan教授担任主席，米兰大学的Pietro Lampertico教授和蔚山医学院的Lim Young-seok教授介绍了他们的研究结果。

陈教授表示，与2000-2005期相比，2011年至2015年期间50岁或以上的慢性乙型肝炎患者增加了约两倍。此外，与2000  -  2005年相比，2011  -  2015年慢性乙型肝炎患者慢性肾病，骨质疏松症和骨质减少的比例分别增加了16％，6％和8％。

Lampertico教授解释了患者衰老的动态变化。

“新推出的慢性乙型肝炎治疗Vemlidy因其改善的血浆稳定性，有效的药物输送以及改善的肾脏和骨骼安全性而受到关注，”他说。 “在大型3期临床试验的96周结束时，与Viread相比，Vemlidy表现出较差的抗病毒疗效，改善肾脏和骨骼安全性以及高阻力障碍。”

他补充说，最近的研究还证明，Vemlidy的ALT正常化率也高于Viread。

有了这样的结果，Lampertico教授介绍了最新发现，ALT水平的早期正常化可以降低肝癌的发病率。

该公司于2005年至2016年对21,182名使用替诺福韦地索普西富马酸盐（TDF）和恩替卡韦（ETV）治疗的慢性乙型肝炎患者进行了一项队列研究，随访期为12个月。

结果，达到ALT正常化值（男性<30 U / L，女性<19 U / L）的患者的肝细胞癌发病率为2.7％，显着低于未达到ALT正常化的患者。期。

据意大利专家称，在12个月时ALT水平高于2倍正常上限（ULN）的患者肝癌发病率约为6％，而1至2倍ULN患者的发病率约为4.6％。

Lim Young-seok教授还表示，TDF组在口服抗病毒药物中的肝癌发病率低于ETV组。

“国家队列和医院队列研究表明，TDF治疗组的肝癌发病率低于ETV治疗组，”Lim教授说。

[email protected]

hp121

该公司于2005年至2016年对21,182名使用替诺福韦地索普西富马酸盐（TDF）和恩替卡韦（ETV）治疗的慢性乙型肝炎患者进行了一项队列研究，随访期为12个月。

结果，达到ALT正常化值（男性<30 U / L，女性<19 U / L）的患者的肝细胞癌发病率为2.7％

这数据也不知道该怎么看，10年累计吗？？